Table 2.
Baseline demographic and disease characteristics of patients who achieved remission in the consecutive measurement
| Remission | |||
|---|---|---|---|
| DAS28-ESR (n = 1160) | CDAI (n = 930) | SDAI (n = 946) | |
| RF+, % | 82.9 | 83.8 | 83.8 |
| RF, average, IU/ml, mean (SD) | 71.4 (100.2) | 88.7 (189.0) | 86.6 (183.3) |
| ESR, mm/h, mean (SD) | 12.2 (8.5) | 17.8 (14.4) | 17.4 (13.9) |
| CRP, mg/L, mean (SD) | 1.7 (3.9) | 2.5 (8.4) | 1.8 (4.0) |
| Measurement interval, mo., mean (SD) | 12.2 (6.5) | 12.4 (6.3) | 12.4 (6.3) |
| MTX usage, % | 61.3 | 61.9 | 61.4 |
| MTX, mg, mean (SD) | 7.6 (3.0) | 7.5 (2.8) | 7.5 (2.9) |
| Prednisolone usage, % | 12.5 | 9.9 | 9.1 |
| Prednisolone, mg, mean (SD) | 4.1 (7.8) | 4.7 (10.1) | 4.5 (10.0) |
| bDMARD or tsDMARD usage, % | 44.3 | 43.1 | 43.7 |
| TNFα-i, % | 23.7 | 25.8 | 26.5 |
| IL6-i, % | 18.6 | 10.3 | 10.1 |
| CTLA4-Ig, % | 3.8 | 6.4 | 6.4 |
| JAK-i, % | 0.1 | 0.6 | 0.7 |
IL6-i interleukin 6 inhibitor, JAK-i Janus kinase inhibitor, TNFα-i tumor necrosis factor inhibitor